Pressure BioSciences Announces the Achievement of a Critical Milestone in Revolutionary Nanoemulsification Technology Development

Pressure BioSciences, Inc. | October 07, 2020

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("UST™")-based nanoemulsification system.  Following achievement of this milestone, the Company has begun to build the initial "Alpha" unit of the commercial model. Once built, tested, and approved, the Company will immediately proceed to build an additional 15 ready-for-sale systems, thus enabling PBI to meet its goal of shipping the BaroShear K45 UST System in early (Q1/Q2) 2021. Based on the Company's patented UST platform, the BaroShear K45 is a unique breakthrough nanoemulsification system designed to resolve one of the most substantive problems facing manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products), and other products containing oil-based active ingredients that are at best poorly soluble in water.  As with any oil-based product, it is difficult for the water-based biochemistry of humans and other animals to access and absorb the active ingredients hidden within oil drops. Poor water solubility leads to lower absorption and bioavailability of active ingredients, which makes it particularly difficult to design and deliver proper dosing of the desired compound. More recently, growing science around nanoemulsion development has shown that oil-based active ingredients manufactured into high quality nanoemulsions have delivered dramatically increased absorption and bioavailability, resulting in higher quality finished products for the consumer.

Spotlight

Time-lapse imaging of DU145 prostate cancer spheroids. Cells were first cultured on Cell-able plates. After 4-7 days, media was switched with 100nM anti-cancer drug paclitaxel plus Caspase-3/7 (green stain indicating apoptosis) and ethidium homodimer-1 (red stain indicating necrosis). Cells were imaged on the ImageXpress Micro System every 30 minutes for 72 hours.


Other News
INDUSTRIAL IMPACT

Cellarity Expands Leadership Team to Continue Evolution of a Breakthrough Platform to Encode Biology and Purposefully Create New Medicines

Cellarity | February 11, 2022

Cellarity, a life sciences company founded by Flagship Pioneering to encode and simulate human biology to reimagine the way we create medicines, announced today the expansion of its executive leadership team with three key appointments. As Chief Scientific Officer, Laurens Kruidenier, Ph.D., will lead the continued evolution of Cellarity’s platform and pipeline and oversee cross functional integration across all aspects of computation, drug creation, and optimization. As Chief People Officer, Anna O’Driscoll will lead the development of human resources and talent development strategies to enable the fast growth of Cellarity and make the company a top place to work for talent. As Senior Vice President and Head of Data and Software Engineering, Parul Doshi will spearhead the development of a leading and scalable data infrastructure to support the entire drug creation and development process. “We are building a transformative company and bringing together a strong team of people with a track record of making things happen. Laurens is not only an exceptional translational scientist, with experience and success advancing primary research into clinical-stage programs, he is also a team and company builder, helping integrate and mature drug discovery platforms.” Fabrice Chouraqui, Ph.D., CEO of Cellarity and a CEO-Partner at Flagship Pioneering Dr. Chouraqui continued, “Anna brings deep experience in talent and leadership development in the biotech industry, and she is known for her passion to positively impact the employee experience. Parul not only brings broad expertise in data infrastructure across the entire pharma value chain, from preclinical and clinical to tech operations and commercialization but also hands-on expertise in software engineering. I am excited that these top leaders have joined us at this pivotal time as Cellarity grows our team, advances key programs, and scales a pipeline of important new therapeutics.” Cellarity has developed unique capabilities to encode biology and model computationally the changes that occur between health and disease to design breakthrough medicines. Cellarity's transformative approach to drug creation looks beyond an individual molecular target to understand the complex biological network of cellular changes that underlie the start and progression of a disease. Built at the confluence of systems biology, single cell data, and machine learning, the Cellarity platform leverages a more complete view of cell biology to purposefully create drugs. Since all diseases stem from a disorder at the cellular level, Cellarity’s approach can be applied to virtually every disease and uncovers new biology and treatments that are unlikely to be found through target-based discovery. “Despite the tremendous progress the industry has made in advancing medical treatments, most diseases do not have curative therapies, and there are thousands of conditions that lack treatments,” said Dr. Kruidenier. “I’m impressed with Cellarity’s drug creation engine, which looks beyond the single target and embraces the full complexity of human disease. I look forward to working with the team to realize the truly transformative nature of the Cellarity platform and advance into the clinic novel medicines in diverse therapeutic areas to meet a wide range of patient needs.” Laurens Kruidenier, Ph.D., Chief Scientific Officer Dr. Kruidenier has more than 25 years of experience in discovery research, both in academic settings as well as in the life sciences industry and a track-record of success in drug discovery and development, driving research programs into clinical study and integrating teams and technologies for growth and scale. Prior to joining Cellarity, Dr. Kruidenier was Chief Scientific Officer (CSO) at Prometheus Biosciences, a precision medicine company in the immune-mediated disease space. At Prometheus, he helped mature the company from an early, seed-stage Cedars-Sinai-spinout into a Nasdaq-listed, platform-driven portfolio company with three active Phase 2 clinical trials. Previously, he held the roles of Vice President of Discovery at Second Genome, where he was responsible for a portfolio of microbiome programs and Head of GI Immunology Research at Takeda Pharmaceuticals, where he was responsible for developing the global discovery research and business development strategy into inflammatory diseases of the bowel. Earlier in his career, Dr. Kruidenier held various positions at different discovery units at GlaxoSmithKline, where he led preclinical teams and projects in immuno-inflammation, epigenetic, and protein degradation drug discovery. He completed his post-doctoral training at the University of London and holds an M.Sc. in medical biology from Utrecht University and a Ph.D. in mucosal immunology from Leiden University. His research has resulted in multiple publications in top tier scientific journals, including Nature. Anna O’Driscoll, Chief People Officer Ms. O’Driscoll has more than a decade of experience in human resources and was most recently Vice President of Human Resources at Alnylam Pharmaceuticals, where she worked in roles spanning R&D, Commercial, Corporate Functions, Learning and Development, and Employee Relations as Alnylam evolved from a research organization to a leading biotech company. Prior to Alnylam, she was Head of Talent Strategy and Process at Shire and in the Human Resources Leadership Development Program at Johnson & Johnson. Ms. O’Driscoll graduated with an MBA from the Institute of Chartered Financial Analysts and a bachelor’s degree in marketing and languages from Dublin City University. Parul Doshi, Senior Vice President, Head of Data and Software Engineering Ms. Doshi has more than twenty years of experience in information technology (IT) and software engineering and was most recently Head of IT & Digital for Takeda’s Vaccine division. She spent the past 16 years at Takeda, in roles of increasing seniority across several divisions of the company. She notably led the IT programs to launch oncology products NINLARO® and ALUNBRIG® as well as the consolidation of the Vaccines Business Unit to Cambridge, Massachusetts and integration of ARIAD Pharmaceuticals post acquisition. Prior to Takeda, Ms. Doshi worked as a developer at Patni Computer Systems, servicing major companies such as Fidelity Investments and LEGO®. Ms. Doshi graduated with an MBA in information technology and finance from Savitribai Phule Pune University, and a bachelor’s in economics and applied statistics from the University of Rajasthan. About Cellarity Cellarity's mission is to fundamentally transform the way medicines are created through the development of the first full stack digital cell. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, model interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity’s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering. About Flagship Pioneering Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $140 billion in aggregate value. To date, Flagship has deployed over $2.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 42 transformative companies, including Axcella Health (Nasdaq: AXLA), Codiak BioSciences (Nasdaq: CDAK) Denali Therapeutics (Nasdaq: DNLI), Evelo Biosciences (Nasdaq: EVLO), Foghorn Therapeutics Indigo Ag, Kaleido Biosciences (Nasdaq: KLDO), Moderna (Nasdaq: MRNA), Omega Therapeutics (Nasdaq: OMGA), Rubius Therapeutics (Nasdaq: RUBY), Sana Biotechnology (Nasdaq: SANA), Seres Therapeutics (Nasdaq: MCRB), and Sigilon Therapeutics.

Read More

MEDICAL

Relevate Health Acquires ConneXion360

Relevate Health | April 26, 2022

Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems. The addition of ConneXion360 expands the Relevate Health suite of HCP engagement marketing solutions for its clients with precision messaging at the point-of-care and point-of-prescribing and Key Account Messaging for 1:1 engagement, complemented by ConneXion360's National Broadcast capabilities and OnDemand platform for "non-personal" engagement. The combination enables Relevate Health's clients to gain access to difficult-to-reach health systems and HCPs via ConneXion360's industry-leading Treatment Perspectives Recruitment Network. These proven solutions will be integrated into Relevate Health's proprietary ElevatedRelevance℠ data platform to cultivate unique and actionable content, market selection, and Key Opinion Leader identification insights for its clients. Relevate Health's comprehensive suite of data-driven HCP Engagement solutions solves the last-mile challenge that many brands face in connecting their creative campaign to target HCP audiences. Relevate Health's digital activation services and marketing solutions plug into existing omnichannel infrastructure and spans the gamut from 1:1 to mass engagement. Bringing ConneXion360's 1:1 engagement, Key Account Messaging, immersive video, and national broadcast capabilities into the Relevate Health suite of products and technology offer new brand-building opportunities for our clients, Quite simply, it means more access to HCPs by the Reps, MSLs, and KAMs, richer opportunities to scale nationally using local data, and deeper omnichannel engagement. For clients seeking a digital-first omnichannel agency, we complement our highly differentiated engagement solutions with class-leading agency services, and digital activation capabilities that help our clients achieve their ambitious growth objectives." Relevate Health CEO Jeff Spanbauer. Relevate Health delivers innovative, integrated HCP omnichannel engagement solutions that are configured to meet clients' specific market challenges. Its unmatched capabilities in "non-personal" promotion, immersive video, peer-to-peer engagement, field rep access, and field rep enablement make Relevate Health the premier marketing partner. Relevate Health delivers precision, segmented, and scalable engagement solutions that overcome the increasing HCP access hurdles. Relevate Health is known for its use of data and machine learning to create locally relevant messages that are scalable, By adding ConneXion360's Treatment Perspectives Recruitment Network and our portfolio of proprietary Treatment Perspectives National & Local HCP Message Engagement Solutions, we can engage target HCPs with more precision, personalization, and relevancy at both national & local levels. Our clients now have access to a single premier partner with a full suite of product-driven, data-based solutions that deliver proven brand growth and extraordinary ROI among previously hard-to-engage HCP audiences." George Griffith, Co-Founder & CEO of ConneXion360. The acquisition of ConneXion360 marks the third transaction by Relevate Health since taking on funding from Denver-based private equity firm Mountaingate Capital in late 2020. Relevate Health's comprehensive system of marketing solutions enables clients of all sizes to deploy a platform that fits their needs. With this acquisition, Relevate Health becomes a single omnichannel partner that addresses the full range of HCP engagement challenges, from 1:1 to National Broadcast, providing field personal as well as brand, digital, and medical leaders with solutions that change HCP's behavior and deliver benchmark beating ROI. Relevate Health, founded in 2007, is an award-winning healthcare marketing agency for pharmaceutical, biotech, and medical device brands, recognized by MM&M, PM360, MedAdNews, and more. ConneXion360 is the leading Health System and HCP Recruitment Network that specializes in creating access for its clients to Health Care Professionals through its proprietary Treatment Perspectives Recruitment Network, National Broadcast platforms, and precision messaging at the point-of-care and the point-of-prescribing.

Read More

MEDICAL

Asep Medical Holdings Inc. Announces Additional Listing to the OTCQB Venture Market in the U.S.

SEPSIS | April 25, 2022

Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce its recent successful listing on the OTCQB Venture Market in the US. The Company will be trading under the stock symbolOTCQB: SEPSF and will continue to sell its common shares on the CSE under the stock symbol CSE: ASEP. Asep Inc. will officially commence trading on the OTCQB as of the market opening today. The Company is also pleased to announce that it has also met the requirements for an account with the Depository Trust Company (DTC). The DTC is one of the world's largest securities depositories and acts as a limited-purpose trust company that will provide safekeeping through electronic record-keeping of securities balances. It will also serve as the Company's clearinghouse to process and settle trades as well as providing liquidity enhancement. Trading on the OTCQB is a significant milestone. It gives us added access and visibility with U.S. institutional and retail investors interested in the biotech and healthcare industries. The listing is expected to provide us with added liquidity and a diversified investor base in a large established public market. In parallel to the CSE, we expect to develop a strong shareholder base in the U.S. to achieve an improved valuation considering the innovative nature of our therapeutic and diagnostic technologies, as we strive to impact patients around the globe." Chairman and CEO Rudy Mazzocchi. Our leading technologies are directed to major worldwide issues with enormous economic impacts. This OTCQB listing will enable us to more effectively engage with knowledgeable investors outside Canada who support innovative and effective solutions." Dr. Robert E. W. Hancock, the Company's Founder and COO. OTCQB is recognized by the United States Securities and Exchange Commission as an established public market. The OTCQB platform enables companies to provide current public information that investors need to analyze, value and trade a security. An extensive network of data distributors and media partners ensures that trade data, news and disclosure are available to broker-dealers, market data providers, and investors. On the OTCQB, investors get an exchange-comparable information experience, convenient trading through their preferred broker or financial advisor, transparent pricing with real-time quotes, and trusted disclosure. ABOUT ASEP MEDICAL HOLDINGS INC. Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections. Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The SepsetER test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation (i.e., in the emergency room), while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis. ABOUT SEPSIS Sepsis is the body's dysfunctional response to infection and is very common, occurring in 49-million individuals globally. Recently the situation has worsened since sepsis is the cause of death in most patients who die from COVID-19. Sepsis is tremendously complex, and early symptoms are relatively non-specific, including fever, fatigue, hyperventilation and a fast heart rate — symptoms can also occur in other diseases. The most severe form of the disease, which occurs for up to one-half of all patients with suspected sepsis, leads to multi-organ failure and, in 23% of cases, death. Current diagnostic tools deliver results after approximately 24-36 hours, often delaying the initiation of treatment.

Read More

DIAGNOSTICS

Oncode Institute and ArgoBio Launch Laigo Bio, a Targeted Protein Degradation Biotech With Programs in Oncology and Neurological Disorders

ArgoBio and Oncode Institute | February 08, 2022

ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR. The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of disease applications. The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases. In contrast to other small molecule approaches, this results in an efficient and sustained degradation of target receptors, potentially resulting in superior efficacy in the clinic than modalities currently being employed by other emerging protein degradation technologies. Initially driven by Madelon Maurice, who will join as the Principal Investigator, Laigo Bio is gearing up for preclinical lead development in the coming months, generating proprietary biologics for a selection of targets to showcase its potential. Laigo Bio receives strong support from seasoned entrepreneurs Neill Moray Mackenzie at ArgoBio and Emil Pot at Oncode, who will prepare the company for a Series A investment round as it aims to initiate its first clinical studies in 2025. Dr. Neill Moray Mackenzie at ArgoBio is a veteran of the IO field and Mr Emil Pot is an IP & business development expert at Oncode with 25 years of experience in life sciences. Chris De Jonghe, Valorization Director of Oncode Institute, said: “SureTACsR is building on the innovative ideas that Dr. Maurice has initially validated with the support of Oncode’s Technology Development Fund. With the foundation of Laigo Bio, another exciting step forward is made towards the translation of Dr. Maurice’s innovations into effective, and tailored therapies for cancer patients. We are thrilled to join forces with ArgoBio in this initial seed round and consider it as a token of great confidence in the potential of this platform technology.” Madelon Maurice of the UMC Utrecht, said:“We are extremely happy that ArgoBio is supporting my long-standing research here at the UMC Utrecht on how to interfere with signalling alterations that drive oncogenesis and bringing a team of experienced scientists and entrepreneurs to help with its translation to the clinic.” Dr. Neill Moray Mackenzie of ArgoBio, said: “This is exactly why we put ArgoBio together last year – to fund these early-stage opportunities. I am especially pleased that Madelon Maurice, a renowned KOL in the field, is leading this novel approach to protein degradation which has great potential to open up a completely new biology in the field of cancer therapy.” “Targeted protein degradation is an exciting space and has gained validation in clinical studies with many players now entering the field. One key differentiator here is sustained degradation of cell membrane bound proteins with a biologic, which is a very novel approach, and we believe holds a lot of promise in oncology and many neurological indications. We look forward to supporting Madelon, Neill and Emil in their journey at Laigo Bio.” Shobhit Dhawan of Oncode Bridge Fund About Argobio Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology, and immunology. Argobio selects and incubates these projects with the goal to create biotech companies and develop them up to a significant Series A financing. Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. About Oncode Institute Oncode Institute unites more than 900 excellent fundamental cancer researchers in the Netherlands. Our mission is to stimulate innovations in the diagnosis and treatment of cancer. The ultimate goal is to help patients survive, improve the quality of life for those affected and contribute to a more affordable healthcare system. Oncode Institute translates fundamental insights into the biology of cancer into new diagnostics, new drugs and innovative treatments. Oncode’s three strategic pillars to improve patient outcomes are Excellent Science, Collaboration and Valorization. Oncode is funded by The Dutch Cancer Society, together with the Ministries of Economic Affairs & Climate, Education Culture & Science and Health, Welfare & Sport, and Health~Holland, with a total amount of €120 million until 2022. About Oncode Bridge Fund The Oncode Oncology Bridge Fund provides early-stage financing to help the creation and growth of new enterprises based on the science of Oncode Investigators. The Bridge Fund aims to accelerate the translation of innovative cancer research of the Oncode labs into treatment options, diagnostic methods and research tools that benefit patients and society as a whole. About UMC Utrecht UMC Utrecht is one of the top-ranked academic medical centers in Europe with the core tasks of care, research and education. With more than 12,000 employees, UMC Utrecht, of which the Wilhelmina Children's Hospital is a part, is one of the largest public healthcare institutions in the Netherlands and the largest employer in the Utrecht region. Our mission: together we improve the health of people and create the care of tomorrow. Together we create more value, because we believe that every person counts. About Laigo Bio Laigo Bio is based on the research from the laboratory of Professor Madelon Maurice, known internationally for her contributions to the understanding of Wnt signaling, a key pathway for stem cell maintenance and tissue renewal. A main focus of her work is to uncover the mode-of-action of membrane-bound E3 ligases that control Wnt receptor turnover and are frequently mutated in cancer.

Read More

Spotlight

Time-lapse imaging of DU145 prostate cancer spheroids. Cells were first cultured on Cell-able plates. After 4-7 days, media was switched with 100nM anti-cancer drug paclitaxel plus Caspase-3/7 (green stain indicating apoptosis) and ethidium homodimer-1 (red stain indicating necrosis). Cells were imaged on the ImageXpress Micro System every 30 minutes for 72 hours.

Resources